Back HIV/AIDS

HIV / AIDS

World AIDS Day: World Health Organization Urges Scale-Up of HIV Self-Testing

The World Health Organization (WHO) this week launched new guidelines encouraging countries to support self-testing in an effort to get more people to learn their HIV status -- the first step toward getting on effective treatment, achieving viral suppression, halting disease progression, and preventing onward HIV transmission. WHO estimates that only 60% of people with HIV are aware of their status, and says that self-testing can help countries meet the UN target of diagnosing 90% of all people with HIV by 2020.

alt

World AIDS Day: CDC Releases New HIV Diagnosis and Prevalence Data

In advance of World AIDS Day, the Centers for Disease Control and Prevention (CDC) released its latest report on recently diagnosed HIV infections in the United States. The new HIV Surveillance Report, which covers data through 2015, shows that HIV diagnoses have decreased among both women and men, and among African Americans, Latinos, and whites, but have risen among young people age 25-29. As people with HIV live longer thanks to effective antiretroviral treatment, HIV prevalence has reached an all-time high of more than 955,000 people.

alt

HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy

A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus 2 NRTIs for treatment-experienced HIV patients, according to a report at the International Congress on Drug Therapy in HIV Infection last month in Glasgow.

alt

HIV Glasgow: 4-Days-On-3-Days-Off HIV Treatment Controls Viral Load in Pilot Study

An experimental "4 days on, 3 days off" antiretroviral regimen kept viral load fully suppressed in 96% of people for 48 weeks in a French study presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. The study recruited people whose viral load had been fully suppressed on standard treatment for a median of 4 years, not people who had started therapy recently.

alt

HIV Glasgow: Darunavir/Ritonavir + Lamivudine Matches Triple-Drug HIV Therapy

Simplifying antiretroviral therapy to a 2-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a 3-drug regimen in people with suppressed viral load, Spanish investigators reported at the International Congress on Drug Therapy in HIV infection (HIV Glasgow) last month in Glasgow.

alt

HIVR4P 2016: The Long Tail Problem -- Injectable PrEP Trial To Be Extended Due to Drug Persistence

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of people who were given the experimental injectable drug cabotegravir as HIV pre-exposure prophylaxis (PrEP), the drug was still measurable in their body a full year after their last injection.

alt

HIV-Positive People May Lose More Years of Life from Smoking than from HIV/AIDS

People with HIV on effective antiretroviral treatment who smoke cigarettes may incur more risk of death and reduction in life expectancy from smoking than from HIV/AIDS-related conditions, according to a study described in the November 3 advance edition of the Journal of Infectious Diseases.

alt